Viekira Pak information for patients

Since October 1, 2016, GPs in New Zealand can prescribe Viekira Pak and Viekira Pak-RBV (with Ribavirin) to treat the hepatitis C virus. Viekira Pak is a DAA (Direct-Acting Antiviral) which has cure rates of 90+ per cent, fewer side effects and a shorter treatment duration compared to previous treatment. Viekira Pak is funded for people with hepatitis C genotype 1a or 1b of the virus.

Harvoni was also funded in New Zealand in 2016. This DAA is funded for people with decompensation (liver failure) and is prescribed by a specialist.

If you qualify for the above treatment, please visit your GP or specialist to discuss accessing the funded treatment.

Please let your doctor know in advance that you are seeking hepatitis C treatment.

Helpful links: 

More medications which treat everyone with hepatitis C are expected to be funded in the next few years.

Design by Paradigm | Developed by Snipesoft
© The Hepatitis Foundation of New Zealand 2016